LAB · XBRL financial data

Standard Biotools financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (LAB's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	138	131	98	106	174	85
Cost of goods and services sold	—	—	61	56	90	43
Gross profit	—	—	37	50	84	43
Research and development	36	38	38	26	62	26
Selling, general and administrative	98	99	115	88	157	110
Total operating expenses	189	198	214	127	259	153
Operating income (loss)	(51)	(67)	(116)	(77)	(175)	(110)
Interest expense	4	4	4	5	—	—
Other income (expense)	1	0	1	7	(5)	4
Income tax expense (benefit)	(1)	(4)	(3)	0	1	(38)
Net income (loss)	(53)	(59)	(190)	(75)	(139)	(75)
Earnings per share, basic USD per share	(0.74)	(0.78)	(2.43)	(0.94)	(0.52)	(0.20)
Earnings per share, diluted USD per share	(0.74)	(0.78)	(2.43)	(0.94)	(0.52)	(0.20)
Weighted average shares, basic millions of shares	72	76	78	79	353	382
Weighted average shares, diluted millions of shares	72	76	78	79	353	382

Fiscal years (LAB's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	69	28	81	52	167	121
Short-term investments	0	0	84	—	—	—
Marketable securities	—	0	84	63	126	67
Accounts receivable	25	18	17	20	34	13
Inventory	20	21	21	21	41	20
Prepaid and other current assets	4	4	4	3	9	5
Total current assets	118	72	209	158	376	454
Property and equipment, net	18	28	26	24	43	19
Right-of-use asset	38	37	34	31	29	27
Goodwill	107	106	106	106	111	—
Total assets	325	275	390	323	612	568
Accounts payable	9	11	8	9	12	5
Accrued liabilities	15	9	6	9	31	30
Total current liabilities	54	50	43	109	66	108
Lease liability, non-current	38	38	34	30	26	25
Total liabilities	186	181	161	160	141	143
Accumulated deficit	(677)	(736)	(926)	(1,001)	(1,186)	(1,261)
Total stockholders' equity	139	95	(81)	(148)	472	424
Total liabilities and equity	325	275	390	323	612	568
Common shares outstanding (cover page) millions of shares	75	77	79	290	379	390

Fiscal years (LAB's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(53)	(59)	(190)	(75)	(139)	(75)
Stock-based compensation	14	16	15	13	32	30
Depreciation and amortization	—	3	6	13	—	—
Net cash from operating activities	(15)	(44)	(89)	(43)	(143)	(74)
Purchases of property and equipment	13	13	4	3	8	8
Net cash from investing activities	40	(12)	(88)	20	363	27
Proceeds from issuing common stock	20	0	—	—	—	—
Share repurchases	—	0	1	5	40	0
Repayments of long-term debt	0	1	0	—	—	—
Net cash from financing activities	21	16	231	(7)	(103)	1
Net change in cash	46	(40)	53	(30)	116	(46)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Standard Biotools	270	20	(10)*	392.6M	46.2 quarters	Q2 FY26 10-QJun 30, 2026
Aquestive Therapeutics	90	7.6	(7)*	125.7M	8.4 quarters	Q3 FY26 10-QSep 30, 2026
Siga Technologies	118	41	15*	71.8M	—	Q2 FY26 10-QJun 30, 2026
Ocugen	100	1.5	(12)*	339.1M	8.2 quarters	Q2 FY26 10-QJun 30, 2026
Abeona Therapeutics	56	11	(17)*	57.2M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Tonix Pharmaceuticals Holding	176	14	(42)*	17.2M	4.2 quarters	Q2 FY26 10-QJun 30, 2026
Vanda Pharmaceuticals	62	70	(28)*	60.5M	1.7 quarters	Q3 FY26 10-QSep 30, 2026
Nektar Therapeutics	39	10	(76)*	34.1M	9.0 quarters	Q2 FY26 10-QJun 30, 2026
Aura Biosciences	68	not reported	(33)*	103.7M	2.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.